Balance Sheet
Accounts PayablesAccumulated ExpensesAssetsCash & Current InvestmentsCash & EquivalentsCommon EquityCurrent AssetsCurrent LeasesFinished GoodsInventoryLiabilities and Shareholders EquityLong-Term Deferred TaxLong-Term InvestmentsNon-Current AssetsOperating LeasesOther Accumulated ExpensesOther Non-Current AssetsOther Non-Current LiabilitiesPayablesPrepaid AssetsProperty, Plant & Equipment (Net)Property, Plant & Equipment (Net)ReceivablesReceivables - NetReceivables - OtherRetained EarningsShareholder's EquityShares OutstandingShort-term InvestmentsTotal Current LiabilitiesTotal LiabilitiesTotal Non-Current LiabilitiesTreasury SharesTreasury SharesWork In Process
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Consolidated Net IncomeCost of RevenueEBITEBITDAEBTEPS (Basic)EPS (Weighted Average and Diluted)Gross ProfitIncome from Continuing OperationsIncome towards Parent CompanyNet Income towards Common StockholdersNon Operating IncomeOperating ExpensesOperating IncomeOther Operating ExpensesProfit After TaxResearch & DevelopmentRevenueSelling, General & AdministrativeShares OutstandingShares Outstanding (Diluted Average)Shares Outstanding (Weighted Average)Tax ProvisionsTax RateTax Rate
Others
Cost of RevenueEBIATGross ProfitLeasesMachine, Furnitures, Fixtures & OtherOther Gross PP&E AdjustmentsOther Gross PP&E AdjustmentsReceivables - NetReceivables - OtherShares IssuedShares OutstandingShares OutstandingShares Repurchased
Ratios

Corcept Therapeutics (CORT) Shares Outstanding (2016 - 2026)

Corcept Therapeutics (CORT) has disclosed Shares Outstanding for 15 consecutive years, with $107.3 million as the latest value for Q1 2026.

  • For Q1 2026, Shares Outstanding rose 1.27% year-over-year to $107.3 million; the TTM value through Mar 2026 reached $107.3 million, up 1.27%, while the annual FY2025 figure was $142.5 million, 3.46% up from the prior year.
  • Shares Outstanding hit $107.3 million in Q1 2026 for Corcept Therapeutics, up from $106.0 million in the prior quarter.
  • Across five years, Shares Outstanding topped out at $108.2 million in Q1 2023 and bottomed at $102.5 million in Q2 2023.
  • Average Shares Outstanding over 5 years is $105.5 million, with a median of $105.3 million recorded in 2025.
  • Year-over-year, Shares Outstanding fell 8.81% in 2022 and then grew 1.88% in 2025.
  • Corcept Therapeutics' Shares Outstanding stood at $107.8 million in 2022, then decreased by 4.11% to $103.4 million in 2023, then increased by 1.65% to $105.1 million in 2024, then rose by 0.81% to $106.0 million in 2025, then rose by 1.29% to $107.3 million in 2026.
  • According to Business Quant data, Shares Outstanding over the past three periods came in at $107.3 million, $106.0 million, and $105.1 million for Q1 2026, Q4 2025, and Q3 2025 respectively.